Key facts
- This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Sep 2022, 16:18.
Jack Anders - 01 Sep 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RVMD
- Reported as of
- 01 Sep 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Sep 2022, 16:18:21 UTC
- Prior SEC filing
- 22 Jun 2022
- Next SEC filing
- 21 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jack Anders
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 02 Sep 2022.
Change
- Previous filing in this sequence was filed on 22 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVMD
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +49%
- Price
- $0.000000
- Shares after
- 30,405
- Date
- 01 Sep 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RVMD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 01 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- $21.61
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 25,964 restricted stock units.
Footnote F2
One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.